NO20044091L - Anvendelse av substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on for fremstilling av medikamenter som inhiberer pankreatisk lipase - Google Patents

Anvendelse av substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on for fremstilling av medikamenter som inhiberer pankreatisk lipase

Info

Publication number
NO20044091L
NO20044091L NO20044091A NO20044091A NO20044091L NO 20044091 L NO20044091 L NO 20044091L NO 20044091 A NO20044091 A NO 20044091A NO 20044091 A NO20044091 A NO 20044091A NO 20044091 L NO20044091 L NO 20044091L
Authority
NO
Norway
Prior art keywords
preparation
oxdiazol
alkoxy
phenyl
substituted
Prior art date
Application number
NO20044091A
Other languages
English (en)
Inventor
Guenter Mueller
Hubert Heuer
Stefan Petry
Karl Schoenafinger
Armin Bauer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20044091L publication Critical patent/NO20044091L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives anvendelse av substituerte 3-fenyl-5-alkoksy-l,3,4-oksdiazol-2-oner, samt deres farmakologisk godtagbare salter og syreaddisjonssalter for fremstilling av legemidler som viser en hemmende virkning på den pankreatiske lipase, PL.Videre beskrives anvendelse av forbindelser med formel 1 der restene har de nærmere angitte betydninger, samt deres farmasøytisk godtagbare salter og syreaddisjonssalter for fremstilling av et legemiddel for profylakse eller terapi av obesitas eller diabetes mellitus Type 1 og 2.
NO20044091A 2002-02-28 2004-09-27 Anvendelse av substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on for fremstilling av medikamenter som inhiberer pankreatisk lipase NO20044091L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10208986A DE10208986A1 (de) 2002-02-28 2002-02-28 Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
PCT/EP2003/001560 WO2003072098A1 (de) 2002-02-28 2003-02-17 Verwendung substituierter 3-phenyl-5-alkoxy-1,3,4-oxdiazol-2-one zur herstellung von arzneimitteln mit hemmender wirkung an der pankreatischen lipase

Publications (1)

Publication Number Publication Date
NO20044091L true NO20044091L (no) 2004-09-27

Family

ID=27740557

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044091A NO20044091L (no) 2002-02-28 2004-09-27 Anvendelse av substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on for fremstilling av medikamenter som inhiberer pankreatisk lipase

Country Status (20)

Country Link
EP (1) EP1482929A1 (no)
JP (1) JP2005519079A (no)
KR (1) KR20040101250A (no)
CN (1) CN1638766A (no)
AR (1) AR038702A1 (no)
AU (1) AU2003210292A1 (no)
BR (1) BR0308045A (no)
CA (1) CA2477005A1 (no)
CO (1) CO5611144A2 (no)
DE (1) DE10208986A1 (no)
HR (1) HRP20040783A2 (no)
HU (1) HUP0500093A2 (no)
IL (1) IL163719A0 (no)
MA (1) MA27173A1 (no)
MX (1) MXPA04007480A (no)
NO (1) NO20044091L (no)
PL (1) PL371310A1 (no)
RU (1) RU2004128932A (no)
TW (1) TW200400026A (no)
WO (1) WO2003072098A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014495A (es) 2004-06-17 2007-03-01 Cytokinetics Inc Compuestos, composiciones y metodos.
RU2007119315A (ru) 2004-10-25 2008-11-27 Зольвай Фармасьютиклз Гмбх (De) Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US7989455B2 (en) 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
MX2010006882A (es) * 2007-12-25 2010-10-05 Kissei Pharmaceutical Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica.
TW201028406A (en) 2008-12-23 2010-08-01 Bial Portela & Ca Sa 5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use
CN103086859B (zh) * 2011-11-08 2015-11-11 清华大学 2,4-二羟基-5,6-取代-1-卤代苯衍生物、其合成方法及其应用
EP3676243A4 (en) * 2017-09-01 2021-05-26 Curtin University SYNTHETIC DERIVATIVES OF OLEOYL-LYSOPHOSPHATIDYLINOSITOL (OLEOLYL-LPI) AND ASSOCIATED USES
CN109879839B (zh) * 2019-03-12 2023-04-25 沈阳大学 6-哌嗪甲基-7-羟基苯并呋喃类化合物及其医药用途
IL321884A (en) * 2020-02-07 2025-09-01 Cytokinetics Inc Nampat modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19942354A1 (de) * 1999-09-04 2001-03-08 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln
KR100790763B1 (ko) * 2000-03-07 2008-01-03 사노피-아벤티스 도이칠란트 게엠베하 치환된 3-페닐-5-알콕시-1,3,4-옥스디아졸-2-온 및 이를 포함하는 호르몬 민감성 리파아제 억제용 약제

Also Published As

Publication number Publication date
DE10208986A1 (de) 2003-09-11
MA27173A1 (fr) 2005-01-03
CO5611144A2 (es) 2006-02-28
JP2005519079A (ja) 2005-06-30
BR0308045A (pt) 2004-12-21
HUP0500093A2 (hu) 2005-04-28
RU2004128932A (ru) 2005-04-10
MXPA04007480A (es) 2004-11-10
TW200400026A (en) 2004-01-01
HRP20040783A2 (en) 2005-04-30
AR038702A1 (es) 2005-01-26
AU2003210292A1 (en) 2003-09-09
PL371310A1 (en) 2005-06-13
KR20040101250A (ko) 2004-12-02
EP1482929A1 (de) 2004-12-08
WO2003072098A1 (de) 2003-09-04
CA2477005A1 (en) 2003-09-04
IL163719A0 (en) 2005-12-18
CN1638766A (zh) 2005-07-13

Similar Documents

Publication Publication Date Title
NO20072542L (no) Pyrimidinderivat kondensert med ikke-aromatisk ring
NO20055680L (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
TWI255817B (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
NO20060908L (no) Substituerte tazol-benzoisotiazoldioksidderivater, deres fremstilling og anvendelse
NO20050648L (no) Heterocyklisk substituerte benzoylureaer, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter
WO2003011880A1 (fr) Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
NO20051871L (no) Opioidreseptorantagonister
WO2003063864A3 (fr) Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
WO2005082414A3 (en) Concomitant drugs of a sulfonamide and another therapeutic agent
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
SE0202462D0 (sv) Novel use
TW200615266A (en) Organic compounds
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20052914L (no) Terapeutiske forbindelser
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
NO20051709L (no) Kystallforbindelse for fast oralt medikament samt fast oralt medikament omfattende denne til behandling av dysuria
DK1213296T3 (da) Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
SE0202429D0 (sv) Novel Compounds
NO20054868L (no) CaSr antagonist
NO20073830L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
NO20044091L (no) Anvendelse av substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on for fremstilling av medikamenter som inhiberer pankreatisk lipase

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application